Amphastar Pharmaceuticals Posts FY 2025 Results as Baqsimi Integration Peaks
Amphastar Pharmaceuticals (AMPH) has released its financial results for the fourth quarter and full year of 2025, marking a critical milestone in its transition toward a proprietary-led product portfolio. The results highlight the continued performance of Baqsimi and Primatene Mist as the primary drivers of the company's revenue growth and margin expansion.